Zobrazeno 1 - 10
of 527
pro vyhledávání: '"Jeffrey W, Tyner"'
Autor:
Alan S. Futran, Tao Lu, Katherine Amberg-Johnson, Jiayi Xu, Xiaoxiao Yang, Saidi He, Sarah Boyce, Jeffrey A. Bell, Robert Pelletier, Takao Suzuki, Xianhai Huang, Heng Qian, Liping Fang, Li Xing, Zhaowu Xu, Stephen E. Kurtz, Jeffrey W. Tyner, Wayne Tang, Tao Guo, Karen Akinsanya, David Madge, Kristian K. Jensen
Publikováno v:
iScience, Vol 27, Iss 5, Pp 109693- (2024)
Summary: The USP7 deubiquitinase regulates proteins involved in the cell cycle, DNA repair, and epigenetics and has been implicated in cancer progression. USP7 inhibition has been pursued for the development of anti-cancer therapies. Here, we describ
Externí odkaz:
https://doaj.org/article/ad0bc59a163a477bae0474b6a3ff6a2d
Autor:
Wenwen Chien, Jeffrey W. Tyner, Sigal Gery, Yueyuan Zheng, Li-Yan Li, Mohan Shankar Gopinatha Pillai, Chehyun Nam, Neil A. Bhowmick, De-Chen Lin, H. Phillip Koeffler
Publikováno v:
Journal of Ovarian Research, Vol 16, Iss 1, Pp 1-14 (2023)
Abstract Background Standard platinum-based therapy for ovarian cancer is inefficient against ovarian clear cell carcinoma (OCCC). OCCC is a distinct subtype of epithelial ovarian cancer. OCCC constitutes 25% of ovarian cancers in East Asia (Japan, K
Externí odkaz:
https://doaj.org/article/085f030e8b1144f18f14b1e5bcb913e7
Autor:
Myles Vigoda, Chase Mathieson, Nathaniel Evans, Carolyn Hale, Jennifer Jennings, Olivia Lucero, Sophia Jeng, Daniel Bottomly, Daniel Clayburgh, Peter Andersen, Ryan Li, Daniel Petrisor, Jeffrey W. Tyner, Shannon McWeeney, Molly Kulesz-Martin
Publikováno v:
Cancer Biology & Therapy, Vol 23, Iss 1, Pp 309-317 (2022)
In this study, we report a differential response of mitogen-activated protein kinase–kinase (MEK) inhibitor trametinib in 20 head and neck squamous cell carcinoma (HNSCC) patients’ tumor-derived cell cultures. Relatively sensitive and resistant c
Externí odkaz:
https://doaj.org/article/b341787595d24a049de4dd01f9d67b72
Autor:
Kyle A. Romine, Daniel Bottomly, William Yashar, Nicola Long, Matthew Viehdorfer, Shannon K. McWeeney, Jeffrey W. Tyner
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionThe implementation of small-molecule and immunotherapies in acute myeloid leukemia (AML) has been challenging due to genetic and epigenetic variability amongst patients. There are many potential mechanisms by which immune cells could infl
Externí odkaz:
https://doaj.org/article/9251dcb7a94c4cb194fdc06f503f7fdd
Autor:
Elana Thieme, Tingting Liu, Nur Bruss, Carly Roleder, Vi Lam, Xiaoguang Wang, Tamilla Nechiporuk, Geoffrey Shouse, Olga V. Danilova, Daniel Bottomly, Shannon K. McWeeney, Jeffrey W. Tyner, Stephen E. Kurtz, Alexey V. Danilov
Publikováno v:
Cell Death and Disease, Vol 13, Iss 3, Pp 1-11 (2022)
Abstract Aberrant B-cell receptor (BCR) signaling is a key driver in lymphoid malignancies. Bruton tyrosine kinase (BTK) inhibitors that disrupt BCR signaling have received regulatory approvals in therapy of mantle cell lymphoma (MCL). However, respo
Externí odkaz:
https://doaj.org/article/6ba6538ef93547b086ba5fe9d9f53329
Autor:
Tsz-Yin Chan, Christina M. Egbert, Julia E. Maxson, Adam Siddiqui, Logan J. Larsen, Kristina Kohler, Eranga Roshan Balasooriya, Katie L. Pennington, Tsz-Ming Tsang, Madison Frey, Erik J. Soderblom, Huimin Geng, Markus Müschen, Tetyana V. Forostyan, Savannah Free, Gaelle Mercenne, Courtney J. Banks, Jonard Valdoz, Clifford J. Whatcott, Jason M. Foulks, David J. Bearss, Thomas O’Hare, David C. S. Huang, Kenneth A. Christensen, James Moody, Steven L. Warner, Jeffrey W. Tyner, Joshua L. Andersen
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
The mechanisms underlying the activity of non-receptor tyrosine kinase, TNK1, in cancers are unclear. Here the authors show that MARK mediates 14-3-3 and TNK1 interaction which restrains TNK1 activity, while the release of TNK1 from 14-3-3 leads to T
Externí odkaz:
https://doaj.org/article/3bf3573d63094261ac7abe05b09d7ee9
Autor:
Brian S. White, Suleiman A. Khan, Mike J. Mason, Muhammad Ammad-ud-din, Swapnil Potdar, Disha Malani, Heikki Kuusanmäki, Brian J. Druker, Caroline Heckman, Olli Kallioniemi, Stephen E. Kurtz, Kimmo Porkka, Cristina E. Tognon, Jeffrey W. Tyner, Tero Aittokallio, Krister Wennerberg, Justin Guinney
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-11 (2021)
Abstract The FDA recently approved eight targeted therapies for acute myeloid leukemia (AML), including the BCL-2 inhibitor venetoclax. Maximizing efficacy of these treatments requires refining patient selection. To this end, we analyzed two recent A
Externí odkaz:
https://doaj.org/article/f6bd5ff98ce1490bb82d669c7207b895
Autor:
Jessica Leonard, Joelle SJ Wolf, Michelle Degnin, Christopher A. Eide, Dorian LaTocha, Kyle Lenz, Beth Wilmot, Charles G. Mullighan, Mignon Loh, Stephen P Hunger, Brian J Druker, Marc M Loriaux, Jeffrey W Tyner, Bill H Chang
Publikováno v:
Haematologica, Vol 106, Iss 11 (2021)
Externí odkaz:
https://doaj.org/article/2901a1309bc34ddbb96064c714b750fc
Autor:
Juan Carlos Rivera-Mulia, Takayo Sasaki, Claudia Trevilla-Garcia, Naoto Nakamichi, David J. H.F. Knapp, Colin A. Hammond, Bill H. Chang, Jeffrey W. Tyner, Meenakshi Devidas, Jared Zimmerman, Kyle N. Klein, Vivek Somasundaram, Brian J. Druker, Tanja A. Gruber, Amnon Koren, Connie J. Eaves, David M. Gilbert
Publikováno v:
Blood Advances, Vol 3, Iss 21, Pp 3201-3213 (2019)
Abstract: Human B-cell precursor acute lymphoid leukemias (BCP-ALLs) comprise a group of genetically and clinically distinct disease entities with features of differentiation arrest at known stages of normal B-lineage differentiation. We previously s
Externí odkaz:
https://doaj.org/article/813e5445336443a09e50cbf90d7c35a2
Autor:
Haijiao Zhang, Samantha Savage, Anna Reister Schultz, Daniel Bottomly, Libbey White, Erik Segerdell, Beth Wilmot, Shannon K. McWeeney, Christopher A. Eide, Tamilla Nechiporuk, Amy Carlos, Rachel Henson, Chenwei Lin, Robert Searles, Hoang Ho, Yee Ling Lam, Richard Sweat, Courtney Follit, Vinay Jain, Evan Lind, Gautam Borthakur, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Jorge Cortes, Robert Collins, Daelynn R. Buelow, Sharyn D. Baker, Brian J. Druker, Jeffrey W. Tyner
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
FLT3 is commonly mutated in acute myeloid leukaemia and treatment with FLT3 inhibitors often ends with relapse. Here, the authors perform exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, to show that resistance o
Externí odkaz:
https://doaj.org/article/998f439604e74cef95464ecda676fa5a